Articles tagged with Fatty Liver Disease
A new study published in Lancet Gastroenterology and Hepatology found that a combined screening approach can detect liver damage in people with type 2 diabetes. The method involves elastography, an ultrasound-based technique, which was found to be willing to be adopted by most patients. Early detection of liver fibrosis is crucial, as ...
A new study finds that a blood test using phosphatidylethanol (PEth) can detect liver disease caused by excessive drinking, offering a more reliable alternative to self-reported measures. The test has shown strong correlation with Fibrosis 4, an indicator of liver risk, and could be included in routine blood tests.
Researchers at Karolinska Institutet have identified two types of metabolic-associated fatty liver disease, a liver-specific type and a systemic type that affects other organs. The discovery could lead to improved diagnosis and treatment of this growing patient group, with potential benefits for cardiovascular health.
The novel compound HPH-15 outperforms metformin by activating AMPK at lower doses, improving glucose uptake and reducing fat accumulation in high-fat diet-induced obese mice. Additionally, it exhibits antifibrotic properties, potentially addressing liver fibrosis.
A new study proves a suspected link between poor sleep and MASLD, a liver disorder that affects 30% of adults. Patients with MASLD experience significant sleep fragmentation, waking up 55% more often at night.
Researchers found that tumor cell secreted DNA in extracellular vesicles acts as a 'danger' signal to activate an anti-tumor response in the liver, reducing liver metastasis risk. The discovery improves understanding of cancer progression and anticancer immunity.
A U-shaped association between waist circumference and all-cause mortality was found in women, while a J-shaped trend was observed in men with type 2 diabetes. The study suggests that optimal waist circumference thresholds for minimizing mortality risk are 107 cm for women and 89 cm for men.
Christian Wolfrum will serve as NTU's chief academic officer, overseeing educational and research excellence, while strengthening talent development. He brings experience in translating research into real-world applications, having co-founded biotechnology firm Glycemicon AG.
Researchers from Salk Institute found that specific dietary fats are incorporated into sphingolipids to drive the development of atherosclerotic cardiovascular disease. The team discovered that trans fats are preferentially metabolized by an enzyme, leading to increased lipoprotein secretion and plaque formation.
Researchers developed a mouse model mimicking the liver symptoms of myotonic dystrophy type 1, revealing fatty liver disease and hypersensitivity to medications. The study found that a gene regulating fat synthesis is misspliced in affected livers, providing potential treatment pathways.
Researchers at the University of Leeds have found that bile production is affected by blood flow in the portal vein, which can contribute to high cholesterol levels and fatty liver disease. This breakthrough provides an opportunity for the development of new treatments for cardiovascular disease.
Researchers investigate how liver necroptosis triggers inflammation in both organs, leading to cognitive impairment. Studying aging mouse models, they found that liver necroptosis causes systemic inflammation affecting brain function.
Researchers found inhibiting ACMSD increases NAD+ levels, reducing inflammation and fibrosis in mouse models of MASLD/MASH. Boosting NAD+ production could protect against severe liver damage and cirrhosis.
Researchers found that intestinal absorption of fats plays a crucial role in preventing diet-induced fatty liver disease. The absence of gut hormones, such as proglucagon-derived peptides, prevents fat accumulation by reducing lipid absorption from the intestines.
A study from the University of Copenhagen detected lipid biomarkers in obese children that indicate a higher risk of developing type 2 diabetes, liver, and heart disease later in life. A one-year lifestyle intervention lowered these biomarkers, demonstrating the importance of early intervention for children with obesity.
A team at Medical University of South Carolina identified a pathway to reduce fat accumulation in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). They used a novel stem cell platform and screened 1,100 compounds to find five that more than halved fat droplets on treated liver cells.
Researchers at Sanford Burnham Prebys discovered that specific macrophage subpopulations, including TREM2+, are critical for resolving MASH and liver fibrosis. These cells help reduce inflammation, slow disease progression, and promote healing.
A randomized clinical trial found camu-camu extract reduced liver lipids by 7.43%, while a placebo increased them by 8.42%. The effect is attributed to polyphenols and their relationship with intestinal microbiota.
Scientists discovered a way to kill pancreatic cancer in mice by combining a ketogenic diet with an existing cancer drug. The diet blocks the cancer's only source of fuel, allowing the drug to take effect and shrink tumors. This finding opens a new vulnerability for treating cancer with diet and personalized therapies.
A recent study published in Cell Metabolism reveals a critical link between defects in the urea cycle and the development of fatty liver disease. The researchers found that these defects lead to secondary impairment in energy metabolism, resulting in excessive fat storage and inflammation in the liver.
A new study finds that combining an inhibitor of a metabolic pathway with chemotherapy could improve treatment outcomes in triple negative breast cancer brain metastases. Inhibiting fatty acid synthase, an enzyme critical for cancer cell survival, shows promise in improving chemotherapy efficacy.
Researchers at UCLA Health found that reducing inflammation may not influence the extent of liver fibrosis in MAFLD. The study suggests that other pathways could be more effective in targeting fibrosis and improving outcomes for patients.
A new study sheds light on fatty liver disease MASH's pathology, revealing T cell activation and growth in response to poor diet. The research holds promise for developing a biomarker test to track disease progression before it's at a late stage.
Alcoholic liver disease is a major public health concern in China, influenced by cultural factors and high alcohol consumption. The disease's increasing prevalence and severe complications highlight the need for comprehensive strategies to manage and prevent ALD.
A study reveals that the gene SH2B1 controls feeding and energy expenditure, with mutations associated with obesity and metabolic diseases. Enhancing SH2B activity may offer a promising treatment for obesity and related conditions with fewer side effects.
Researchers found increased liver oxidative stress and impaired antioxidant defenses in a DS murine model. The study suggests potential therapeutic strategies targeting oxidative stress and lipid metabolism to prevent or mitigate liver-related complications.
A study led by the University of Barcelona suggests that pemafibrate could treat the world's most common liver disease, with findings indicating a good safety profile and potential efficacy in reversing fatty liver disease. The drug repurposing approach aims to reduce time and economic costs of bringing new treatments to market.
Researchers found that facial temperatures are associated with chronic illnesses like diabetes and high blood pressure. They discovered specific regions of the face where temperatures correlate with age and health, including the nose, eyes, and cheeks.
Researchers have identified SEMA3A as a critical player in the development of fatty liver disease, where it closes blood vessel 'windows' hindering fat transport. Inhibiting SEMA3A reduces liver fat and improves function.
Researchers have developed a novel patch that can help liver tissue regenerate and inhibit inflammation. The patch demonstrated restored liver function in lab tests and promoted recovery from liver fibrosis in rats, showing great potential for treating liver diseases.
Researchers developed a metabolic health score based on clinical parameters and used it to explore its genetic underpinnings in mice, validating findings in human data. The study identified two significant genetic regions linked to metabolic health and pinpointed candidate genes associated with metabolic traits.
New research reveals that bile acid imbalances contribute to the development and progression of fatty liver disease (MASLD) and alcoholic liver disease (ALD). Targeting bile acid signalling pathways shows promise as a potential treatment approach for these diseases.
Researchers found high GDF15 levels in steatotic liver patients are associated with an increased risk of liver cancer. Combining blood GDF15 levels with liver stiffness indicators can efficiently identify patients at high risk of developing liver cancer and poor outcomes.
Researchers found that Werner syndrome mice experience age-dependent and sex-specific changes in their livers and immune systems, including fatty liver accumulation and altered lipid metabolism. These findings suggest a potential link between immunoglobulin variants and fatty liver progression in the disorder.
Research reveals a three times greater risk for metabolic-dysfunction-associated steatotic liver disease in women with moderate-to-severe vasomotor symptoms compared to those with mild symptom severity. The study highlights the importance of addressing hot flashes and night sweats to assess cardiovascular health.
A new study found that children who are sedentary for more than six hours a day have a significantly increased risk of severe fatty liver disease and liver cirrhosis by young adulthood. Engaging in light-intensity physical activity for at least 3 hours a day can reverse premature liver damage.
Researchers from Ben-Gurion University of the Negev have discovered a link between proteomic biomarkers and liver fat percentage, which may improve patient monitoring and therapy targeting for NAFLD. The study, conducted over 18 months, found that specific protein changes were independently associated with liver fat relative change.
Researchers at USask have discovered a new peptide that lowers lipid accumulation in human liver cells, offering new avenues for treating metabolic diseases. The finding is hopeful news as there's a lack of new therapies available for these diseases.
The STING signaling pathway is crucial in mediating hepatic inflammation and metabolic disturbances in nonalcoholic fatty liver disease. High-fat diet-induced NAFLD is associated with increased STING activity, leading to enhanced pro-inflammatory cytokine production.
A new study reveals that a cancer drug can improve insulin sensitivity and lower blood glucose levels, but eliminating a specific gene related to fat metabolism worsens insulin resistance. The research highlights the interconnectedness of fat metabolism in organs and the need for simultaneous treatment of obesity and insulin sensitivity.
The Endocrine Society will unveil new research on male birth control and anti-obesity medications during ENDO 2024 news conferences. The society's Vitamin D Clinical Practice Guideline is also being shared publicly for the first time, featuring discussions on its recommendations.
A 5:2 diet has been shown to protect against chronic liver inflammation and liver cancer in mice. The study identified two proteins, PPARα and PCK1, that are jointly responsible for the protective effect of fasting.
Researchers at U of T have identified two compounds, diindolylmethane and diindolylethane, produced by gut bacteria that can regulate the nuclear receptor CAR, potentially treating diseases like diabetes, fatty liver disease, and small intestine ulcerative colitis.
Researchers at Karolinska Institutet have discovered a new class of drugs that block mitochondrial function and reverse diet-induced obesity, fatty liver, and diabetes in mice. The treatment increased fat metabolism, leading to drastic weight loss and restored glucose tolerance.
A study of 15 brand-name drugs found that competition from 'skinny label' generics saved Medicare nearly $15 billion from 2015 to 2021. The largest savings were seen for rosuvastatin, pregabalin, and imatinib, with actual spending being $16.8 billion versus projected spending of $31.5 billion.
A study published in Annals of Internal Medicine found that semaglutide is an effective therapy for metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV. The medication, approved for type 2 diabetes treatment, showed significant reductions in liver fat and improved metabolic markers.
Decreased gut bacterial diversity was found in patients with NAFLD, while Faecalibacterium and Ruminococcus 2 were associated with the disease. The study identified a combination of microbiomes and biochemical indexes that distinguished NAFLD from normal livers.
Researchers found a three-component signaling pathway in hepatic stellate cells that leads to collagen production and liver fibrosis. A novel RNA-based treatment, ASO, was designed to block this pathway, preventing fibrosis without side effects.
Researchers found that spinal cord injury triggers abnormal neuronal activity that causes abdominal fat tissue compounds to leak and pool in the liver and other organs. A short course of gabapentin, commonly prescribed for nerve pain, prevented this damaging metabolic effect.
Scientists have discovered genetic variants in BSN and APBA1 genes linked to adult-onset obesity, type 2 diabetes, and fatty liver disease. These variants are associated with a significant increase in obesity risk, highlighting a new biological mechanism for the condition.
Researchers at Gwangju Institute of Science and Technology (GIST) have discovered a novel compound, 11c, a 5HT2A antagonist, which exhibits robust biological activity and a favorable safety profile. The compound has shown promising efficacy in preclinical models and is poised to advance the treatment of metabolic liver diseases.
Researchers have identified a gene responsible for the development of starvation-induced fatty liver in cavefish, which are able to protect their liver due to reduced fat accumulation. This genetic basis has implications for understanding and addressing liver conditions in humans, including Type 2 diabetes and obesity.
Resmetirom, a new medication, has been approved to treat metabolic dysfunction-associated steatohepatitis (MASH), a more advanced stage of MASLD characterized by liver inflammation and scarring. The drug was shown to improve fibrosis and reduce disease progression in patients with MASLD.
Researchers identified a new organelle, MLRO, formed by mitochondrial and lysosomal fusion, which may offer an alternative process to breaking down damaged mitochondria. Understanding MLRO's function could lead to new therapeutic strategies for chronic liver diseases.
Research reveals oestrogen's protective role in preventing fatty liver disease by targeting the TEAD1 protein. The discovery could lead to a new treatment for fatty liver and liver cancer, as well as earlier detection methods.
A new study finds that Latinx children with unreliable access to food at age 4 are nearly four times more likely to develop fatty liver disease later. The researchers recommend earlier screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and ensuring public meal programs offer nutritious meals.
A Phase 2b pilot study found semaglutide reduced liver fat content in people with HIV, with 29% of participants experiencing complete resolution of MASLD. The treatment also led to weight loss and improved blood sugar levels.
A new prediction tool has been developed to identify individuals at high risk for hepatocellular carcinoma (HCC) due to alcohol-related liver disease. The nomogram uses key risk factors, including heavy drinking, age, and diabetes, to predict HCC risk with high accuracy.
A new mouse study reveals that the gut microbiome interacts with the loss of female sex hormones to exacerbate metabolic disease. The research suggests that the gut microbiome contributes to weight gain, fat in the liver, and inflammation, particularly in women after menopause.
Researchers have identified a new mechanism that inhibits glucose synthesis in the liver, which could lead to improved efficiency of current diabetes treatments. The study highlights the role of GDF15 protein in modulating AMPK and reducing liver fibrosis.